Concepedia

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi,

The Lancet Oncology · 2019 · 1.7K citations · 24 references

DOIFull text

Open access

Concepts

References

24

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

, , +16

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

, , +16

A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

Dionisio Martı́n-Zanca, Stephen H. Hughes, Mariano Barbacid · Nature · 1986 · 803 citations · Full text

, , +16

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

Aria Vaishnavi, Marzia Capelletti, Anh T. Le et al. · Nature Medicine · 2013 · 602 citations · Full text

, , +12

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas et al. · The Lancet Oncology · 2018 · 552 citations · Full text

, , +16